Jane Street Group, LLC Adaptimmune Therapeutics PLC Transaction History

Jane Street Group, LLC

$445 Billion
Q3 2024

A detailed history of Jane Street Group, LLC transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Jane Street Group, LLC holds 174,157 shares of ADAP stock, worth $102,752. This represents 0.0% of its overall portfolio holdings.

Number of Shares

174,157

Previous 75,576 130.44%

Holding current value

$102,752

Previous $74,000 122.97%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.92 - $1.39 $90,694 - $137,027	98,581 Added 130.44%	174,157 $165,000
Q2 2024 Aug 14, 2024	BUY	$0.83 - $1.47 $62,728 - $111,096	75,576 New	75,576 $74,000
Q4 2023 Feb 14, 2024	BUY	$0.43 - $0.79 $41,959 - $77,088	97,580 New	97,580 $77,000
Q2 2022 Aug 16, 2022	BUY	$1.33 - $2.28 $58,634 - $100,516	44,086 New	44,086 $75,000
Q1 2022 May 17, 2022	SELL	$1.73 - $4.06 $35,030 - $82,210	-20,249 Closed	0 $0
Q4 2021 Feb 15, 2022	SELL	$3.5 - $5.68 $75,883 - $123,148	-21,681 Reduced 51.71%	20,249 $76,000
Q3 2021 Nov 16, 2021	BUY	$3.44 - $6.37 $38,644 - $71,560	11,234 Added 36.6%	41,930 $216,000
Q2 2021 Aug 16, 2021	BUY	$3.86 - $5.78 $47,790 - $71,562	12,381 Added 67.6%	30,696 $130,000
Q1 2021 May 18, 2021	SELL	$4.9 - $6.83 $49,284 - $68,696	-10,058 Reduced 35.45%	18,315 $97,000
Q4 2020 Feb 17, 2021	BUY	$4.0 - $9.2 $113,492 - $261,031	28,373 New	28,373 $153,000
Q2 2018 Aug 15, 2018	SELL	$10.42 - $13.74 $155,747 - $205,371	-14,947 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$7.1 - $11.56 $106,123 - $172,787	14,947 New	14,947 $168,000

Others Institutions Holding ADAP

# of Institutions

Shares Held

150M

Call Options Held

60.8K

Put Options Held

5.8K

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $96.4M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Adaptimmune Therapeutics PLC Transaction History